SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional
detailed pre-clinical pharmacology and pharmacokinetic data on
ralinepag (APD811), the Company's next-generation, oral, selective
prostacyclin receptor (IP) agonist intended for the treatment of
pulmonary arterial hypertension (PAH), at the 27th International
Congress of the European Respiratory Society (ERS). ERS is
taking place September 9-13, 2017 at
the MiCo Milano Congressi in Milan, Italy.
The presentations will comprise ralinepag IP receptor binding
affinity, selectivity and comparative functional potency versus
approved IP receptor agonists and prostacyclin mimetics. Biological
responses highlighting the pharmacology of ralinepag in rat PAH
models, as well as human platelet and vascular responses in tissues
from PAH patients will be presented.
Presentation Details
Title: The non-prostanoid IP receptor agonist, APD811
(ralinepag) has potent antiproliferative and vasorelaxant
properties in human pulmonary artery
Thematic poster: Experimental PH
Session Number: 293
Presenter: Dr. Lucie Clapp
Poster Number: PA2378
Date/Time: Monday, September
11, 12:50-14:40pm
Location: TP-16 (Hall 4)
Title: Pharmacokinetics and pre-clinical efficacy of
ralinepag (APD811) in humans and rats
Session: New perspectives from experimental models of pulmonary
hypertension
Session number: 528
Oral Presentation Number: OA4662
Date/Time: Wednesday, September 13,
8:30-10:30am
Location: Brown 1 + 2 (South)
About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on
developing novel, small molecule drugs with optimized receptor
pharmacology designed to deliver broad clinical utility across
multiple therapeutic areas. Our proprietary pipeline includes
potentially first- or best-in-class programs for which we own
global commercial rights. Our three most advanced investigational
clinical programs are ralinepag (APD811) which has completed a
Phase 2 trial for pulmonary arterial hypertension (PAH), etrasimod
(APD334) in Phase 2 evaluation for multiple autoimmune indications,
and APD371 in Phase 2 evaluation for the treatment of pain
associated with Crohn's disease. In addition, Arena has
collaborations with the following pharmaceutical companies: Eisai
Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences
(Phase 2 candidate), and Boehringer Ingelheim International GmbH
(preclinical candidate).
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. These
statements may be identified by introductory words such as
"intended," "will," "belief," "potential," "designed" or words of
similar meaning, or by the fact that they do not relate strictly to
historical or current facts. Such forward-looking statements
include statements about the upcoming presentations, the potential
of ralinepag, advancement of our pipeline, our focus, and the
potential of our programs and collaborations. For such
statements, we claim the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from our expectations. Factors that could cause actual
results to differ materially from the forward-looking statements
include: the timing and outcome of research, development and
regulatory review is uncertain; enrolling patients in our ongoing
and intended clinical trials is competitive and challenging; we
expect to need additional funds to advance all of our programs, and
you and others may not agree with the manner we allocate our
resources; our drug candidates may not advance in development or be
approved for marketing; risks related to developing and
commercializing drugs; the risk that Arena's revenues are based in
part on estimates, judgment and accounting policies, and incorrect
estimates or disagreement regarding estimates or accounting
policies may result in changes to Arena's guidance or previously
reported results; government and third-party payor actions,
including relating to reimbursement and pricing; risks related to
relying on collaborative arrangements; the entry into or
modification or termination of collaborative arrangements;
unexpected or unfavorable new data; nonclinical and clinical data
are voluminous and detailed, and regulatory agencies may interpret
or weigh the importance of data differently and reach different
conclusions than Arena or others, request additional information,
have additional recommendations or change their guidance or
requirements before or after approval; topline data may not
accurately reflect the complete results of a particular study or
trial; Arena's and third parties' intellectual property rights;
results of clinical trials and other studies are subject to
different interpretations and may not be predictive of future
results; clinical trials and other studies may not proceed at the
time or in the manner expected or at all; satisfactory resolution
of litigation or other disagreements with others; and those factors
disclosed in our filings with the Securities and Exchange
Commission, including our Form 10-Q for the quarter ended
June 30, 2017. These forward-looking
statements represent our judgment as the time of this release. We
disclaim any intent or obligation to update these forward-looking
statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original
content:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-additional-pre-clinical-data-on-ralinepag-for-treatment-of-pulmonary-arterial-hypertension-at-international-congress-of-the-european-respiratory-society-300514325.html
SOURCE Arena Pharmaceuticals, Inc.